Hoʻomākaukau kulana ʻo Starlix, Novonorm - ka hoʻoponopono regulators koko

ʻAʻole ia e like me ka nateglinide (Starlix), ʻo ka repaglinide (Novonorm) ʻaʻole ia e hōʻemi wale nō i ka postprandial, akā hele wikiwiki hoʻi i ka glycemia, no ka mea ʻoi aku ka lōʻihi o ka pilina me ko ka mea receptor SUR. Akā ʻo nateglinide i kahi liʻiliʻi e kumu i ka hopena o ka hypoglycemic, akā i ka manawa like ʻo kona hopena ma ke pae o HbA1c ma ka liʻiliʻi loa. Maikaʻi lākou i nā mea i kapa ʻia ʻo "naive" medyo sulfanilamides nā mea maʻi me ka maʻi mellitus, i.e. i kēlā mau mea i loaʻa ʻole i nā lāʻau o sulfa.

Nā Hōʻike. Hiki ke noʻonoʻo ʻia ka Glinids e hoʻomaka i ka hoʻolaʻa ʻana no ka T2DM, inā paha i nā poʻe me ka hyperglycemia hoʻokaʻawale a me nā pahuhopu mua o ka ʻai, i kākoʻo ʻia e ka meaʻai a me ka hana kino kūpono. Hiki i nā mea kaulike no ka mālama glinid nā maʻi i makaʻu i ka hoʻomohala ʻana o ka hypoglycemia, inā hoʻi ka pākeke. Hoʻohana lākou i nā mea maʻi e ʻaina ʻole i ka wā i ka lā (1-2 mau manawa), akā i ka manawa like e ʻai i nā mahele nui. Hiki iā lākou ke hoʻohana i nā maʻi me kahi alerio no ka sulfonamides, no ka mea ʻaʻole i pili ke kinipona i nā hāmeʻa iā lākou.

ʻO ka hopena o ka hoʻohaʻahaʻa hē o nā glinides i ka nui, ka mea i manaʻo ʻia e ke kiʻekiʻe o ka HbA 1 c, kahi haʻahaʻa loa ʻia ma mua o ka sulfanilamides a i ka nui o 0.7-1.5% i nā mea maʻi e pane aku nei i ka mālama maʻi. Hiki ke hoʻonohonoho ʻia ʻo Glinides i ka hui pū me nā lāʻau lapaʻau e hoʻohaʻahaʻa i ke kō, ke ʻano, me ka ʻokoʻa o ka sulfonamides, me ia ka mea he wahi maʻamau o ka hana ma ka cell beta. No ia kumu like, ʻaʻole pono e manaʻo i kekahi mai ka hopena o nā mea maʻi me ka sulfonamides i nalowale i ka hopena a i nā mea kūpaʻa mua loa i ka sulfanilamides.

Ma keʻano holoʻokoʻa, ʻo ka hemahema o ka pālolo ka pono o nā maʻi he nui i ka lā, ʻo ka hoʻohaʻahaʻa iho no ka hoʻohaʻahaʻaʻana i ka HbA 1 s ma mua o sulfonamides a i ke kumukūʻai kiʻekiʻe.

Nā maʻi a me nā palena. ʻO nā glinides i contraindicated type type type diabetes mellitus, i ka mea hoʻomohala i ka mea maʻi ketoacidosis a i ʻole me ka hypersensitivity i ʻike ʻia iā lākou, pū kekahi i nā keiki (ʻaʻohe data i ko lākou palekana i ka hihia hope loa). Hiki iā lākou ke hana i ka hypoglycemia, inā paha i nā mea maʻi me ka maʻi hepatic, adrenal a i ʻole pituitary insufficiency, i nā mea nāwaliwali a palupalu. ʻO Glinides i kahi ka liʻiliʻi ma mua o ka sulfonamides e hoʻokūkū i ka hypoglycemia a ma nā mea maʻi i nā maʻi i loaʻa ʻole i ka maʻi hypoglycemic waha a me HbA 1 c

ʻO continicated nā continicated i ka wā hāpai a me ka umauma, ʻoiai ʻaʻole ia i hōʻike ʻia he mau hopena teratogenic, akā e hoʻonāukiuki wale i nā hana a nā kauā i ka wā hāpai a me ka lactation i nā fetuses a me nā mauʻu hou. Hoʻokahi wale nō holoholona i hoʻokau i nā hana o ka pālolo me ka waiū, akā ʻaʻole i hana ʻia nā noiʻi like i nā wahine hānai. I kēia mea, ua contraindicated lākou i ka wā lactation.

Hiki ke kuhikuhi ʻia ka Glinides no ka hāʻule ʻana o ka renal me ka ʻole o kahi kaupalena.

I nā mea liʻiliʻi me ka haʻahaʻa o ka maʻi hepatic, ua kuhikuhi ʻia nā glinides me ka ʻole o ka palena, akā hiki i ka hāhai ʻana i kā lākou metabolism i kekahi mau maʻi, ka mea e hoʻonui ai i ka hopena o ke kōnike o ka glinids a i hōʻemi ʻia kā lākou kūmole a i ʻole ko lākou lawelawe ʻana i nā wā nui e koi ʻia. Ma ka hōʻemi kino o ka ate, ua contraindicated (ʻo ka noiʻi ʻana i kēia ʻano o nā mea maʻi i hana ʻia).

ʻAʻole pili ka pākeke a me ka wahine a me ka wahine a me ka wahine.

ʻO ka hypoglycemia, pākuʻi ʻana o ke ake ʻōpū, sinusitis, nausea, ka maʻi pākia, constipation, arthralgia, ka loaʻa ʻana o ka momona, a me ka hōʻeha o ke poʻo ma waena o nā hopena maikaʻi ʻole i ʻike ʻia me nā glinids.

Hoike ʻike

ʻO Meglitinides (derivatives o ka benzoic acid) kahi papa hou o nā lāʻau lapaʻau e hoʻonui ai i ka nīnūnē o ka insulin. Hoʻokomo ʻia ka Meglitinides i nā lāʻau lapaʻau e like me ka repaglinide a me ka nateglinide.

Hoʻopili pili ka mīkini o ka hana o ka meglitinides i kā lākou hana ma nā kahiki KP hilinaʻi-ATP. Ma lalo o ka mana o meglitinides, ua pani ʻia nā kumuwaiwai K +, ka ulu ʻana o ka cells-sel a me ka hoʻoulu ʻana i ka glucose, e hoʻonui ai i ka huna ʻana o ka insulin i ka pane ʻana i ka glycemia hoʻonui.

ʻO kahi mea nui o ka meglitinides ka mea me kā lākou kōkua, e hoʻihoʻi ka mua o ka hana huna ʻana i ka insulin, a laila, ma muli o ka manawa pokole o ka hana, ʻaʻole i kūkulu ka hyperinsulinemia lōʻihi.

ʻO kahi hiʻohiʻona o nā pharmacokinetics o meglitinides ko lākou hiki ke nānāʻia i ka gastrointestinal tract i kahi manawa pōkole loa.

I loko o ke koko, ʻo ka hapa nui o nā derivatives o ka sulfonylurea a me nā meglitinides e hoʻopili i ka protein o ka plasma (90-99%). Hoʻolālā ʻia ʻo Meglitinides, ma kahi ʻē, hoʻomaka e hana a hana wikiwiki, a ʻo ia kā lākou mea maikaʻi. ʻO kā lākou hana e hoʻomaka wale i kekahi mau minuke ma hope o ka nānā ʻana, akā e mau wale nō ma kahi o 1 hola, no laila e hoʻohana ʻia nā meglitinides me kēlā me kēia manawa.

Lawe ʻia ka metabolism o ka meglitinides e ka puʻuwai, a hoʻoneʻe ʻia nā lāʻau lapaʻau ma waena o nā ʻōpū, e hiki ai iā lākou ke hoʻohana i ka mālama ʻana o nā maʻi me ka maʻi type 2 me ka maʻi hou o ka maʻi hou.

ʻLelo. ʻO kekahi mau laikini pharmacokinetic o meglitinides

Nā hiʻohiʻona o ka hana o ka hana a me ka pharmacokinetics ʻae i ka meglitinides e noho i kā lākou iho kūʻokoʻa ponoʻī i ka mālama ʻana i ka maʻi diabetes 2. Mahalo i kēia mau hiʻohiʻona, loaʻa ka hui i kona inoa ʻelua - nā regulators prandial glycemic.

Hoʻohālikelike ʻia i nā derivatives sulfonylurea, meglitinides haʻahaʻa haʻahaʻa gpremial postprandial, akā hoʻemi lākou i ka pae o ka wikiwiki o ka glycemia.

Lawe ʻia nā Meglitinides ma mua o ka ʻai, a i ʻole me ka ʻai, a i ʻole he mau minuke ma hope o ka ʻai. Ke hoʻi hou nei ka pae i ka 3 mau hola ma hope o ka hoʻokomo ʻana o ka meglitinides, ka mea e kolohe ana i ka huna kino physiological o ka insulin no ka ʻake ʻana o ka meaʻai a hōʻemi i ka hopena o ka hypoglycemia ma waena o nā meaʻai.

Pēlā, kēia mau lāʻau lapaʻau e ʻae i ka mea maʻi i kahi ala maʻalahi loa e pili ana i ka nānā ʻana i ka ʻai. Inā e huʻa ʻoe i ka ʻai, ua heʻa ʻia hoʻi ka lāʻau lapaʻau. He mea koʻikoʻi loa kēia no nā maʻi maʻi ʻōpio e alakaʻi nei i kahi ʻano hana, no ka mea inā e mālama ʻia me ka sulfonylurea, aia kahi hewa o ka hypoglycemia i kēia hihia.

Hāʻawi ʻia i ke kumukūʻai nui o nā lāʻau lapaʻau, ʻo ka mea nui loa o kā lākou ʻoihana i hui pū ai me ka metformin no nā poʻe maʻi e ʻike ʻole nei ka metformin monotherapy i ka uku kūpono o ka maʻi, inā no ka nui o ka pae i ka pae glycemia postprandial. Eia nō naʻe, hiki hiki ke hoʻohana i nā meglitinides e like me monotherapy (kahi kūlike ka hopena i ka derogatives sulfonylurea) a i hui pū ʻia me thiazolidinediones.

Hoʻomaʻamaʻa pinepine ʻia ʻo Meglitinides e nā mea maʻi. ʻO ka hopena maʻamau o nā lāʻau lapaʻau o ka pūʻulu i hōʻike ʻia he hypoglycemia.

Hoʻomoe hoʻomākaukau ʻia Glinides

ʻO nā ʻelele o kēia hui hui pū ʻana:

Hoʻopili i nā hana hoʻonā

ʻO nā lāʻau lapaʻau ma kēia pūʻulu e hana nui i nā cell beta o ka pancreas. Ka hoʻopiʻi ka hopena hopena i kahi protein kūikawā i kapa ʻia ʻo SUR1, ka mea i loaʻa i nā pū beta o ka pancreas a no laila, hoʻoulu i ka huna ʻana o ka insulin.

No laila, nā derivatives o sulfonylurea (i.e., gliclazide, glycoverone, glimepiride) i pili i ka protein like like.

Pehea ka hana ʻana o nā glinids

ʻO ka ʻokoʻa ma ka hana o nā palapala lepo lepo a me nā derogatives o sulfonylurea, ʻo ka hana o ka hana mua me ka ʻoi aku ka hua. Mamuli o kēia, hoʻopau i ka manawa ma mua o ka ʻai ʻana a ma hope iho o ka ʻai ʻana, e hoʻohaʻahaʻa i ke kō, e ala ana ma hope o ka ʻaina a emi ʻole ka hopena o ka glucose.

ʻO ka hopena, hoʻonui ka nui o ka insulin i ke koko. Hiki wale kēia hana inā hiki i nā cell pancreatic i hiki ke hoʻoulu a hūnā.

Ma ke ʻano diabetes type 2, ʻike ʻia nā cell beta he "pau" a ʻaʻole hiki ke hana hou i ka insulin. No laila, aia kahi mea e pono ai e hoʻolauna iā ia i ka hoʻohālikelike o nā inikin subcutaneous, a maikaʻi ʻole ka hoʻohana ʻana o ka pālolo.

ʻO nā glinids i kuhikuhi ʻia

I kekahi mau'āina maʻEulopa, ua hoʻohana ʻia nā glinids e mālama i ka maʻi maʻamau 2 ma ka hui ʻana a me ka hoʻoulu ʻana, a i ʻole ka hui pū me ka meaʻai, ka hoʻomaʻamaʻa ʻana, a me ka metformin.

ʻAʻole hoʻohui ʻia kā lākou hui pū ʻana me nā derivatives sulfonylurea. Eia nō hoʻi, mai hoʻohana i nā glinides inā he maikaʻi ʻole ka sulfonylureas no kēia (i kēia hihia, ʻaʻole e hana nā mea ola glinides).

Nā kuʻi no ka hoʻohana ʻana o ka pālolo

Nui kekahi contraindications i ka hoʻohana ʻana i ka pālolo.

ʻO ka mea nui loa:

• ʻO ka hypersensitivity a i ʻole nā ​​hopena kūlohelohe i nā lāʻau lapaʻau o kēia pūʻulu i ka wā ma mua,
• ʻAno maʻi type 1
• ʻO ka heleʻana o nā hoʻopiʻi maʻi maʻi (ketoacidosis, maʻi koma maʻi - e pono ke mālama i nā ʻano me ka insulin),
• ʻLelo ʻia a me ka lactation,
• ʻO ka hoʻopili maʻi ʻeha.
• Pono e mālama me ka akahele i ka renal a i ʻole hepatic insufficiency, adrenal insufficiency, i ka wā kahiko a i ka hihia o pōʻino ʻole.
• ʻAʻole pono e hana ma nā kūlana i hoʻonui pinepine ʻia ka insulin kino - no ka laʻana, me ka maʻi koʻikoʻi a me nā kaʻina hana hoʻolimalima. I ia mau kūlana, ʻokoʻa ke aʻo ʻana i ka hoʻohana kino ʻana i ka insulin.

Pehea e lawe ai

Lawe ʻia ka lāʻau lapaʻau ma mua koke o a i ʻole wā ʻaina.

ʻAʻole pono e nānā i ka wā o ka ʻai. Eia kekahi, ma hope o ka nīnau ʻana i ke kauka, hiki iā mākou ke hoʻoponopono i ke ʻano o ka lāʻau ma mua o ka ʻai. Ma ke hanana āu i hoʻolālā ai e ʻai ai, hiki iā ʻoe ke hoʻonui.

• ʻO ka nui loa o ka nui o ka repaglinide he 4 mg (ʻoi loa ka nui o kēlā me kēia lā he 16 mg).
• No ka nateglinide, ʻo ka nui loa ka nui o nā lā ma mua o 180 mg.

Inā poina e lawe i ka lāʻau lapaʻau i ka manawa, ʻaʻole pono ʻoe e inu i ʻelua papa me ka papaʻai e hiki mai ana, no ka mea hiki i kēia ke hōʻeha i ka hypoglycemia.

ʻO Glinids a me Meglitinides: ka hana o ka hana no ka maʻi maʻi

No nā makahiki he nui ʻole e hakakā nei me DIABETES?

Ke poʻo o ka Institute: "E haʻihaʻo ʻoe i ka maʻalahi o ka lāʻau e mālama ai i ka maʻi maʻi ma o ka lawe ʻana i kēlā me kēia lā.

ʻO nā ala hou o ka mālama ʻana i ka maʻi maʻi e pili ana i ka hoʻohana ʻana i nā lāʻau lapaʻau therapeutic i pili i nā hui like ʻole no nā kumu therapeutic.

I kēia lā, ʻeono mau ʻanoʻokoʻa o nā lāʻau lapaʻau i hoʻolaʻa ʻia i loko o kahi lāʻau lapaʻau.

Hoʻohana wale ʻia nā lāʻau hoʻoneʻe hoʻoliʻu i ka mea maʻi ke ʻano o ka maʻi diabetes mellitus 2, ʻo ia ka mea ole-insulin.

Aia nā lāʻau āpau i nā hui lāʻau lapaʻau e hiki mai nei.

1. Biguanides.
2. ʻO Glinidam.
3. ʻO Glitazone.
4. Nā mea paʻa o ka glucosidase Alpha.
5. Nā mea hoʻonani o DPP-4.
6. Sulfonamides.
7. Ua hui ʻia.

Hoʻokahi pū ka hui o nā biguanides i hoʻokahi lāʻau lapaʻau - Metformin. Ua hoʻohana ʻia kēia pono hana mai 1994. ʻO ka hāmeʻa ka mea maʻamau i hana ʻia e hōʻemi ai i ke kōpaʻa i ke kino.

Hoʻokomo ʻia ʻo Glitazones i hoʻokahi lāʻau lapaʻau - Pioglitazone. Kōkua ka lāʻau lapaʻau e hoʻonui i nā membrane cell o nā selipila peripheral i insulin a hoʻomaikaʻi i ka pae o nā momona o ka momona.

Hoʻopili ke kumu o ka glucose glucosidase i ka hoʻoneʻe ʻana o nā hāmeʻa, e pale ai i ka kahe o ka glucose i loko o ke kaila koko.

Hoʻopili ke pale DPP-4 i ka luku ʻia ʻana o ka polagoneta-like polipetide 1 (GLP-1) a hoʻoneʻe i ka enzyme DPP-4.

Hoʻohana ʻia ʻo Sulfanilamides e like me nā lāʻau lapaʻau i ka hoʻohaʻahaʻa ʻana a ʻoi ka mea i kaulana loa. Kālana ka hana a nā lāʻau lapaʻau e pili ana i ka hoʻoulu ʻana o ke kaʻina hana o ka insulin i nā ʻenehana pancreatic. I kēia manawa, ua hoʻolālā ʻia nā papa he 4 o ka sulfonamides.

ʻO nā lāʻau hoʻohui i hui pū ʻia he nui nā mea ikaika i ko lākou pūhui.

Hoʻokomo ʻia ka Glinids i nā lāʻau lapaʻau ʻelua i kā lākou hui - ʻo Repaglinide a me Nateglinide. He hopena hoʻonāukiuki nā lāʻau i nā ʻāpana beta o ka pankīnū.

Hoʻopiliʻia me nā hopena hoʻemi i ke kō, ʻo ka pālehu he mau waiwai ʻē aʻe.

• ʻaʻole ia e hoʻopuka i ka paona,
• i ka wā e hoʻohana ai i nā lāʻau lapaʻau o kēia pūʻulu i ka mea maʻi, hiki i ka nui o ka hypoglycemia i mau manawa i hoʻohālikelike ʻia me sulfonamides.

E like me nā lāʻau āpau, ʻo nā huahana no ka pūʻulu pālolo ka nui o nā hopena maikaʻi ʻole:

• i ka wā e hoʻohana ʻia ai, aia ka hiki i ka hoʻomohala ʻana i ka hypoglycemia,
• ʻaʻole ia he mea e pono ai e hoʻohana i kahi lāʻau lapaʻau inā loaʻa i ka mea maʻi ka maʻi o ka maʻa.

Hoʻohana pinepine ʻia nā lāʻau lapaʻau i nā manawa maʻamau e hoʻomaka ana no ka mālama ʻana i ka maʻi mellitus type 2.

Nā ʻōmole a me nā contraindications no ka hoʻohana ʻana o ka pālolo

ʻO ka hōʻike nui no ka hoʻohana ʻana i ka pālolo ka hele ʻana o ke ʻano mellitus type II i ka mea maʻi i ka ʻole o ka hoʻohana pono ʻana mai ka papa mālama ʻia a me ka hana kino.

Hoʻohana ʻia nā lāʻau lapaʻau e pili ana i kēia hui i ka hoʻemi ʻana i ke kiʻekiʻe o nā honi i loko o ke kino o ka mea maʻi.

E like me nā lāʻau lapaʻau, nā lāʻau lapaʻau no ka pūʻulu pālolo he nui o nā contraindications no ka hoʻohana.

ʻO nā hoʻohālikelike i ka hoʻohana ʻana i ka pālolo nā ʻōlelo aʻe:

1. ʻO ka heleʻana o ka hypersensitivity.
2. ʻO ka heleʻana o kahi maʻi maʻi type 1 ma kahi maʻi.
3. ʻO ka hoʻolālāʻana i ke kino o nā kūlana e koi ai i ka therapy insulin.
4. ʻO ka heleʻana o nā pilikia hōʻeha nui ma ka hana o nā keiki a me ke ake.
5. ʻO ka manawa o ka gestation a me ka manawa o ka umauma.

ʻAʻole ia e kuhikuhi i ke kuhikuhi i nā glinids i nā maʻi o nā keiki a me nā wā'ōpiopio ma lalo o ka 18 mau makahiki o ka makahiki he mea hou aku, ʻaʻole pono ke hoʻohana i nā lāʻau lapaʻau no ka mālama ʻana i ka maʻi maʻi i nā maʻi ma mua o 75 mau makahiki o kona mau makahiki.

ʻO nā hopena hopena maʻamau loa o ka hoʻohana ʻana i kēia ʻano lāʻau lapaʻau:

• nā maʻi o ka ʻeha gastrointestinal, i hōʻike ʻia e ke ʻano o ka hoʻokuʻi a me ka manaʻo o nā nausea,
• i kekahi mau hihia, ulu mai nā hopena kūloko, i hōʻike ʻia i ke ʻano o ka ʻāʻī i ka ʻili
• i kekahi manawa aia kahi hoʻonui o ka hana transamylase.

I kekahi mau hihia, aia ka hemahema ʻike, i hele pū me ka fluctuations i ka pae o ka puna i loko o ke kino.

ʻO ka hana o ka hana o ka pālolo

He mea hoʻonāukiuki ʻo Glinides i ka hana ʻana i ka insulin. ʻO kēia mau lāʻau lapaʻau mai nā sulfonamides ʻaʻole wale i ka hoʻolālā, akā ʻo ka pharmacologically. Ua hoʻomohala ʻia nā Glinids e like me nā lāʻau lapaʻau e kōkua ai e hoʻihoʻi a hoʻonui i ka nui o ka insulin hormone pancreatic i hana ʻia e nā cell beta.

ʻO ka Glinids e lawe wale ia i ka wā ʻai, hiki iā ia ke hoʻopili i kahi meaʻai ʻoi aku ka maikaʻi ma ka hoʻohālikelike ʻia i ka wā ke lawe ʻia ai ka sulfonamides.

Aia ʻo Meglitinides kahi hapa pōkole ma mua o ka ola, kahi e hoʻemi ana i ka hopena o ka uluʻana i kahi kūlana hypoglycemic.

I kēia manawa, aia nā meglitinides i ʻelua mau lāʻau lapaʻau - Nateglinide a me Repaglinide.

Kālana ka hana o ka hana i ka lāʻau lapaʻau ma kona hopena i ke ala o ka pā paʻaleka kōlepa o ATP o nā membrane beta-cell. Ke alakaʻi nei kēia i ka depolarization o ke membrane a me ka wehe i nā kanikina kaluna. Ma hope o ka hoʻolaha ʻana i ka lapaleka pancreatic, hoʻonui ʻia nā lāʻau i loko o ka hoʻokomo o nā kaluna calcium i loko o nā sela mai ka intercellular space.

Ke hoʻonui nei i ka hoʻonui ʻana o ka calcium ma ke kōpona e hoʻōla i ke kaʻina o ka hana hana i ka insulin.

ʻAʻole paʻa pono ka pilina ʻo ka meglitinides me nā mea hoʻoponopono selona, ​​no laila, paʻa ka paʻakikī a i paʻa ka manawa pōkole.

Nā hoʻomākaukau maʻi Clinid, i ka wā i hoʻokomo ʻia i loko o ke kino, hiki i ka nui o ke kao i ke koko i hoʻokahi hola ma hope o ka hoʻokele ʻana. ʻO ka bioavailability o nā lāʻau lapaʻau e pili ana i ka 56%.

ʻO ka lawe pū ʻana o nā lāʻau lapaʻau me ka meaʻai ʻaʻole i koʻikoʻi ka manawa e hiki ai i ka manawa kiʻekiʻe o ka hoʻoulu ʻia ʻana o ka mea ikaika i loko o ke koko, a ʻo ka piʻi ʻana o ka nui o ka pūhui ma ka 20%. Hiki i nā Glinides ke hoʻopili i nā protein plasma, ka kiʻekiʻe o ka hoʻopaʻa ʻana ma kahi o 98%.

ʻO ka hapalua o ke ola o ka lāʻau mai ke kino e pili ana i hoʻokahi hola.

Lawe ʻia ka hoʻomākaukau ʻana o ka hoʻomākaukau ʻana o ka hui pālolo me nā feces. I kēia ala, ma kahi o 90% o nā metabolites i kūkulu ʻia i ka wā o ka metabolism ka excreted. Eia kekahi, ʻo ka haʻalele ʻana o ka lāʻau e hana i ka hapa ma o ke ʻano o ka excretory me ka urine.

ʻO ka hemahema o kēia ʻano lāʻau lapaʻau ka mea pono o ka nui o nā lā o nā lāmani holoʻokoʻa i ke ao a me ke kumukūʻai kiʻekiʻe o nā lāʻau lapaʻau.

ʻO ka hoʻohana ʻia o ka lāʻau lapaʻau Starlix

ʻO ka Starlix kahi lāʻau lapaʻau i lawe koke ʻia ma mua o ka ʻai kai i ka wā o ka mālama ʻana i ka maʻi mellitus type 2. ʻO ka palena ma waena o ka lawe ʻana i ka lāʻau lapaʻau a me ka meaʻai ʻaʻole pono e hoʻonui i ka manawa he 0,5.

Ke hoʻohana ʻia nei i ka lāʻau no ka monotherapy, e hōʻike ʻia kahi kau hoʻokahi o 120 mg. ʻO ka lāʻau lapaʻau e pono e hoʻoili i ʻekolu mau manawa i ka lā. Pono ka lawe ʻia i ka lāʻau ma mua o ka ʻaina kakahiaka, ka ʻaina awakea a me ka ʻaina.

Inā ʻaʻole i ʻae ʻia ka regimen i ʻōlelo ʻia e hoʻokō i ka hopena therapeutic i makemake ʻia, hiki ke hoʻonui ʻia i hoʻokahi dosage i 180 mg.

ʻO ka hoʻoponopono ʻana o ka hopena pili i ka lāʻau e hana pinepine ʻia e like me nā hopena o kahi noiʻi noiʻi o nā mākaʻikaʻi HbA1c a me nā hōʻailona glycemia mea i hala i hoʻokahi mau hola ma hope o kahi pāʻina.

Hiki i Starlix, inā pono, e hoʻohana ʻia ma ke ʻano he ʻano ma ka hoʻōla paʻakikī o ke ʻano maʻi mellitus type 2. Hiki i ka lāʻau lapaʻau ke hoʻohana pū me ka metformin.

Ke hoʻohana nei ʻo Starlix i ka hui pū me Metformin, pono ke ʻano he 120 mg ʻekolu mau manawa i ka lā. ʻO ka lāʻau i ka wā o ka lāʻau paʻakikī e lawe i mua o ka papaʻaina.

Ma ka hanana i, i ka wā o ka hopena o ka mea maʻi paʻakikī, ua hoʻokokoke ke kumukūʻai HbA1c i ka hōʻailona hoʻohālikelike i ka physiologically, hiki ke hoʻemi ʻia ka hopena o Starlix i ka pae o 60 mg ʻekolu mau manawa i ka lā ma ka ʻae o ke kauka.

ʻO ka hoʻohana ʻana i ka lāʻau ʻo Novonorm

ʻO ka lāʻau lapaʻau ʻo Novonorm he lāʻau lapaʻau, aia ia ka repaglinide i kahi kahe o ka 0.5, 1 a i ʻole 2 mg ʻo ia ka mea hana nui.

ʻO ka dosage kumu mua no ka maʻi maʻi maʻi ʻĀina o ka 0.5 mg o ka hoʻopua ikaika.

Ke ʻae ʻia nei ka hoʻonui ʻana i ka dosage ma mua o 7-14 mau lā ma hope o ka hoʻomaka ʻana o ka hoʻohana maʻamau i ka lāʻau.

Inā ʻike ʻia ka pili ole o ka puʻuwai me ka maʻi mellitus me ka maʻi mellitus, ua nānā pinepine ʻia ka HbA1c ma mua o 2 mau pule.

No ka mālamaʻana i nā hui pū, ua hoʻohana maikaʻi kā mākou mea heluhelu iā DiabeNot. Ke ʻike nei i ka kaulana o kēia huahana, ua hoʻoholo mākou e hāʻawi iā i kou makemake.

Hoʻohana ʻia ka lāʻau lapaʻau e hoʻohana ʻia ma nā ʻano nui loa:

1. ʻO kahi dosis hoʻokahi o ka lāʻau lapaʻau e pono ʻia me 4 mg o ka lāʻau ikaika.
2. ʻAʻole pono ka hopena o kēlā me kēia lā i ka 16 mg.

ʻO ka manawa kūpono loa no ka lawe ʻana i ka lāʻau lapaʻau he mau minuke 15 ma mua o ka ʻai ʻana, akā hiki nō hoʻi ke lawe i ka lāʻau lapaʻau 30 mau minuke ma mua o ka ʻai ʻana i ka meaʻai a i ʻole ma mua o kona hoʻokō ʻia.

Inā ʻaʻa kahi ʻai e ka mea maʻi, ʻaʻole pono hoʻi e lālau ʻia ka lāʻau lapaʻau.

I ka hoʻokō ʻana i kahi pāʻina āpau, pono hoʻi e hoʻohana i ka lāʻau lapaʻau.

ʻO ka ʻokoʻa nui ma waena o Starlix a me Novonorm ka mea i hiki i ka mea hope ke hoʻohaʻahaʻa i nā pae glucose ʻaʻole wale ma hope o ka ʻai ʻana, akā ma waena o ia mau meaʻai. ʻO kēia ma muli o ka hiki o ka mea hana like ke hoʻohui pū me ka SUR receptor a hana i kahi paʻa paʻa paʻa me ia.

Pono e hoʻomanaʻo hiki i ka Starlix ke hoʻonāukiuki ma ka liʻiliʻi ma muli o ka helehelena o nā hōʻailona o ka hoʻomohala ʻana o kahi kūlana hypoglycemic pākuʻi me Novonorm.

ʻO nā hopena ʻaoʻao a me ka hālea

Ma hope o ka hoʻoponopono waha, ua hoʻomākaukau ʻia nā hoʻomākaukau e pili ana i ka hui glinid i nā ʻōnaehana o ka mea huna o ka insulin i loko o nā pupu beta o ka pancreatic kiko mahele i ka hana a kēia ʻano lāʻau. ʻO ka hoʻohana ʻana i kēia mau lāʻau lapaʻau i ka hana hewa ʻole i nā ʻōkuhi no ka hoʻohana a i ʻole nā ​​ʻōlelo i loaʻa mai ka endocrinologist e hiki ai ke hoʻonāukiuki i ka II mellitus type II, kahi maʻi maʻi endocrine insulin o nā hōʻailona o ka hypoglycemia.

Kēia hopena ma ke kino e pono ai i ka hoʻohana ʻana i nā lāʻau lapaʻau koke ma mua o ka papaʻaina.

Kuhi ʻia nā kānāwai a me nā ʻōkuhi a ke hoʻohana nei i ka lāʻau lapaʻau e pili ana i ka hui pālolo, ʻaʻole ia e hoʻokau i kahi kūlana hypoglycemic.

ʻOi aku ka maikaʻi o kēia mau lāʻau inā hoʻohana i nā wā mua o ka hoʻomohala ʻana o ka maʻi type 2. Hoʻokaʻawale ʻia nā ʻina mua o ka hoʻomohala ʻana i ka maʻi ma ka manawa o kēia manawa ka hana o ke ʻano hana no nā maʻi pancreatic, nona ke kuleana o ka insulin, mālama ʻia.

ʻO ka hopena o ka hoʻomohala ʻana i kahi kūlana hypoglycemic i ke kino o ka mea maʻi me ka maʻi diabetes type 2 ua like like me ka pinepine o ka hoʻomohala ʻana o ka hypoglycemia me ka hoʻohana ʻana o derivatives sulfonylurea me kahi wā pōkole e hana ai.

Ke hoʻohana ʻana i ka hoʻomākaukau o ka hui pālolo, pono e mālama ʻia ka mālama kūikawā inā loaʻa ka maʻi maʻi i ka aʻalolo. ʻO kēia no ka hopena o ka hoʻonā nui o nā lāʻau lapaʻau e lawe ʻia ana i loko o nā pūpuna o nā ate. ʻO nā lāʻau ʻelua e pili ana i kēia hui e hoʻopili i ka cytochrome P-350, e pili ana i nā ʻāpana o ka pūnao enzyme system.

Pono e mālama pono ʻia ka hoʻohana ʻana i nā lāʻau lapaʻau i kahi kūlana hikiʻole ke mālama pono i ka pae o ka glycemia i loko o ke kino. ʻO ia mau ʻano, ʻo ia hoʻi ka hoʻomohala ʻana o ka maʻi i ke kino, i ka hōʻeha koʻikoʻi, i ka wā ʻoihana. Inā hele kēia kūlana, pono e hoʻoneʻe ʻia ka lāʻau lapaʻau a hoʻololi i ka hoʻohana ʻana i ka lāʻau o ka insulin.

Aia ka ʻike e pili ana i nā lāʻau lapaʻau e hoʻohana ʻia ana i ka mālama ʻana i ka maʻi maʻi i ka wikiō ma kēia ʻatikala.

Nā ʻano o Insulin

Hāʻawi ka hale hana lapaʻau i nā mea maʻi me ka manawa wale nō i ka pōkole o ka ultrashort pōkole, akā he lōʻihi a lōʻihi ka hana i waena, holoholona, ​​human genetic engineering. No ka mālamaʻana i ka maʻi mellitus mua a me ka lua o ka maʻi mellitus, hoʻokaʻawale nā ​​endocrinologists i nā maʻi, e pili ana i ke ʻano, ka pae ʻana o ka maʻi, nā ʻano like ʻole o ka lāʻau like, ʻano like me ka lōʻihi o ke kau ʻana, ka hoʻomaka a me ka hana kiʻekiʻe.

ʻO ka mea hoihoi: No ka manawa mua, i ka 1921, ua hoʻokaʻawale ʻia ka insulin mai ka pancreas o nā holoholona. ʻO Ianuali ma hope iho ua hōʻailona ʻia e ka hoʻomaka ʻana o nā hoʻokolohua lapaʻau o ka hormone i ka poʻe. I ka makahiki 1923, ua loaʻa i kēia makana nui loa o ka ʻoi aku ka Pisa no ka Nobel.

Nā ʻano o insulin a me kā lākou ʻano o ka hana (papa):

Pehea e hoʻoholo ai i ka wā e hoʻokele ai, nā kuʻina, nā ʻano like ʻole o ka hoʻomākaukau ʻana o ka insulin. Hoʻokahi wale nō ka endocrinologist e pane i kēia nīnau. ʻAʻole e hoʻolaʻa pilikino i kekahi hihia.

Nā hiʻohiʻona o ka hana o ka insulin pōkole

Hoʻopuka kahi kino olakino i kahi hormone, i nā manawa a i nā cell beta o ka mokupuni o Langerhans o nā pancreas. ʻO ke synthole hormone hoʻonāukiuki ke kumu i hana ʻole ʻia, kahi maʻi metabolic i kokoke o nā ʻōnaehana a pau o ke kino a me ka hoʻomohala ʻana i ka maʻi diabetes. I nā hoʻomaka mua o ka hoʻomohala ʻana o ka maʻi, maʻi pinepine nā maʻi i nā insulins pōkole.

1. ʻO ka inika pōkole kahi haʻahaʻa o ka wikiwiki (mai 20 a 40 mau minuke), no laila e pono ka lōʻihi o kekahi manawa ma waena o ka hoʻonā o ka hormone a me ka ʻai.
2. ʻO ka nui o ka meaʻai e pono ke ʻai ma hope o ka hoʻoulu ʻia ʻana o ka insulin wikiwiki e kūpono i ka hopena o ka lāʻau lapaʻau. ʻAʻohe hihia e hoʻololi pono ʻia ka nui o kaʻai ʻana i ka meaʻai. ʻOi aku ka nui o nā meaʻai e alakaʻi i ka hyperglycemia, liʻiliʻi i ka hypoglycemia.
3. ʻO ka hoʻomaka ʻana o ka hana pōkole hana pōkole e koi i nā kīmaha - ma hope o nā hola 2-3 i kahi kiʻekiʻe i ka hana o ka lāʻau lapaʻau, no laila pono ke kino i ka powa.

Hoʻomanaʻo: ʻO ka manawa no ka helu ʻana i ka manawa a me ka ʻōleka hōʻike - hōʻike nā maʻi i kā lākou mau hiʻohiʻona pilikino o ke kino. No laila, ua hoʻoholo ʻia ka ʻāʻālua a me ke manawa e ka endocrinologist no kēlā me kēia maʻi.

Pono e hoʻopili ʻia nā ʻōkuhi me kahi syringe insulin maikaʻi wale nō a i ka manawa kikoʻī. Hoʻohana ʻia ka lāʻau ma nā subcutaneously, i kekahi manawa intramuscularly. ʻO ka pūnaewele injection wale nō e hoʻololi iki, ʻaʻole pono e laka ma hope o ka pau ʻana a hiki ke holo maikaʻi ka lāʻau i loko o ke koko.

He mea nui ia e loli ʻole ka mea maʻi i ke kauka e hele nei i ke kaʻina o ka mālama mau ʻana i ka lāʻau lapaʻau, ʻo ia iho ʻo ia e nānā pono i kāna meaʻai a me ke ʻano hana.

• ua pane koke ka insulin wikiwiki i ka komo ʻana o nā honi,
• mālama i ka lāʻau lapaʻau e mālama i kahi pae o ka hormone i ke kahe koko.

Pehea e hoʻolālā kūʻokoʻa ai i ka manawa o ka lāʻau lapaʻau

• pono ʻoe e komo i ka palena o ka lāʻau 45 mau minuke ma mua o ka ʻai ʻana,
• nānā i ka glucose i kēlā me kēia mau minuke ʻelima,
• inā hāʻule ka pae glucose i ka 0.3 mmol, pono koke ʻoe e ʻai i ka meaʻai.

ʻO ke hoʻoponopono kūpono ʻana i ka hormone e alakaʻi i ka mālama pono o ka maʻi mellitus i ka maʻi a me ka pale ʻana i nā hoʻopiʻi. ʻO ka makeʻana o ka hoʻomākaukau ʻana o ka insulin no nā pākeke mai 8 PIECES a hiki i 24 PIECES, no nā keiki - ʻaʻole ʻoi aku ma mua o 8 PIECES i kēlā me kēia lā.

Nā Hoʻohui

E like me kekahi lāʻau lapaʻau, loaʻa i ka insulin wikiwiki nā contraindications a me nā hopena paha.

• hepatitis, ʻehā o ka duodenum a me ka ʻōpū,
• nephrolithiasis, ʻoihana,
• kekahi mau puʻuwai naʻau.

Hōʻike ʻia nā hopena maikaʻi ʻole i ka hana hewa ʻana o ka dosage: nāwaliwali nui, ke kau nui ʻana, ka hoʻolalele ʻana, ke kō, nā palpitations, aia nō nā mea i hala me ka hala ʻole o ka hoʻomaopopo ʻana, coma.

Nā pōkuhi Insulin pōkole

Pehea e hūnā ai i nā inoa o nā lāʻau like ʻole i kahi lāʻau lapaʻau? Ka hoʻololi wikiwiki ʻana i ka insulin, kanaka a i kā lākou ʻanoʻelima, ua hoʻololi ʻia:

Hoʻohālikelike

ʻO ka insulin pōkole he lāʻau lapaʻau i kauoha ʻia e kahi endocrinologist e mālama i ka maʻi maʻi. I ka mea e mālama pono ai ka mālama ʻana a ʻaʻole i lawe i ka pōʻino i loko o ke ʻano o ka hypo-, hyperglycemia, paʻa i ka dosis, ka manawa o ka hoʻokele ʻana, ka hoʻoponopono ʻāina. Hoʻopili i ka lāʻau lapaʻau me nā mea hoʻomohala wale ma hope o ka nīnau ʻana i kahi kauka. He mea nui loa ia e nānā pono kūʻokoʻa i ke kiʻekiʻe o ka glucose i ke koko, e hoʻopaʻa pinepine ʻia i nā hoʻokolohua, a hoʻoponopono pono i nā mea pale a me ka mālama ʻana.

Nā hiʻohiʻona o thiazolidinediones

ʻO Thiazolidinediones, i nā huaʻōlelo glitazones kekahi ʻano o nā lāʻau o ke koena haʻahaʻa i makemake e hoʻonui i ka hopena olakino o ka insulin. No ka mālama ʻana i ka maʻi mellitus no ka hoʻomaka ʻana no ka maʻi maʻamau - mai ka makahiki 1996. Hoʻokuʻu loa ʻia e like me ka papa kuhikuhi.

ʻO Glitazones, ma ka hana o ka hana hypoglycemic he hopena kūpono ma ka ʻōnaehana cardiovascular. ʻO ka hana aʻe i nānā ʻia: antithrombotic, antiatherogenic, anti-inflammatory. Ke lawe nei i ka thiazolidinediones, e emi ana ka pae o ka hemoglobin glycated ma ka awelika o 1.5%, a hoʻonui ka kiʻekiʻe o ka HDL.

ʻO ka hopena me nā lāʻau lapaʻau o kēia papaʻaina ʻaʻole mea emi iki ma mua o ka lāʻau me ka Metformin. Akā ʻaʻole lākou i hoʻohana i ka hana mua me ka maʻi diabetes type 2. ʻO kēia ke kumu o ka paʻakikī o nā hopena ʻaoʻao a me ke kumukūʻai kiʻekiʻe. I kēia lā, hoʻohana nā glitazones e hoʻohaʻahaʻa i ka glycemia me nā derivatives a me ka metformin. Hiki iā lākou ke hoʻokaʻawale ʻia a me nā mea ʻokoʻa me kēlā me kēia lāʻau lapaʻau, a i hui pū ʻia.

Loaʻa a me nā ponoʻole

I waena o nā hiʻohiʻona o nā lāʻau lapaʻau ke kūpono a maikaʻi ʻole:

• hoʻonui i ke kaupaona kino ma 2 kg ma ka awelika,
• ʻO kahi papa nui o nā hopena pili
• Hoʻomaikaʻi i ka ʻōlelo lipid
• Hoʻomaʻa maikaʻi ka hopena i ka pale ʻana i ka insulin
• ka hana haʻahaʻa haʻahaʻa haʻahaʻa hoʻohālikelike i ka metformin, sulfonylurea derivatives,
• kahe koko koko
• ho'ēmi i nā mea e pili ana i ka hoʻomohala ʻana o ka atherosclerosis,
• kaomi wai, a ma muli o ia, ʻo ka piʻi ʻana o nā puʻuwai aloha,
• hoʻemi i ka kūloko o ka iwi, hoʻonui i ka nui o ka puʻuwai,
• hepatotoxicity.

Nā hana hana i ka hana

Hana ʻia nā Thiazolidinediones i nā mea hoʻopiʻi, e hoʻonui ai i ka hoʻoili ʻana a me ka hāpai ʻana o ka glucose i nā puna. ʻO ka hana a nā hāmeʻe i ka palani, a me nā iwi adipose a hoʻomaikaʻi. Eia kekahi, ʻoi aku ka nui o ka hopena ma ke kiʻekiʻe o nā hōʻailona ʻelua hope loa.

ʻAʻole hoʻonā ʻia nā Glitazones i ka hana ʻana i ka insulin e ka pancreatic β-cells.ʻO ka hōʻemi o ka hana e loaʻa i ka hōʻemi ʻana i ka insulin i ka pale ʻana o nā kiko peripheral a me ka hoʻonui ʻana i ka hoʻohana ʻana o nā glucose i nā kino. ʻO ka hopena hoʻohaʻahaʻa gula ma ke ʻano, e like me ke kānāwai, e hele malie. ʻIke ʻia ka pae liʻiliʻi o ka ʻaihue ʻai wikiwiki ʻana ma hope o kahi hana o ʻelua mahina. Kau pū ʻia ka ʻohana me ka loaʻa ʻana o ka paona.

Loaʻa kahi holomua i ka kaohi metabolila ma o ka hoʻohaʻahaʻa ʻana i ke kō. Ke hui pū ʻia me nā derivatives metformin a me sulfonylurea, ua hoʻomaikaʻi ʻia ka mana glycemic i nā mea maʻi me ka maʻi maʻamau 2, a me nā pae nui o ka plasma nui. Hoʻokumu ka Glitazones i ke alo o ka insulin.

Lapa loli nā ʻano ʻoiacacininetic ma muli o ka lāʻau. ʻAʻole e pili i ka kāne a me nā makahiki o ka mea maʻi. Me ka pōʻino o ka maʻi i nā maʻi, e loli ia i ka pharmacokinetics.

Nā hōʻailona a me nā contraindications

Thiazolidinediones e kuhikuhi ʻia no ka non-insulin-dependant type (type 2 diabetes):

• like monotherapy no kēlā poʻe maʻi e kāohi i ke kiʻekiʻe o ka glycemia me ka lāʻau ʻole (kaʻai a me ka hana kino),
• ʻoiai, he mau mea ʻelua e hui pū ana me ka hoʻomākaukau ʻana o ka sulfonylurea,
• ʻoi aku ka lawelawe ʻana i ka metformin no ka ʻoluʻolu o ka glycemic control,
• me he lā triple lapaʻau o "glitazone + metformin + sulfonylurea",
• hui me ka insulin
• hui me insulin a me metformin.

I waena o nā contraindications i ka lawe ʻana i nā lāʻau lapaʻau:

• holomua,
• hapai / lactation
• makahiki i 18 makahiki
• huni kūlohelohe - koʻikoʻi a me ke kaumaha
• hōʻeha paʻa ka naʻau
• pilikia nui ʻole ʻo ia.

Haʻawina wikiō e pili ana i ka hoʻomākaukau ʻana o ka pūʻulu thiazolidinedione:

Nā hopena hopena

Ma waena o nā hopena hopena ma hope o ka lawe ʻana i ka thiazolidinediones ʻo ia ka:

• i nā kāne - kūlohelohe kāne.
• ka ulu naʻau,
• ka haʻalele ʻana o ke kūlana hormonal,
• ua hoʻonui nui ʻia o nā ate o nā ate,
• anemia
• huahuʻi,
• hipololeka,
• keiki a me ka ʻōpū,
• loaʻa ka paona
• hoʻonui nui momona
• ʻeha ka ʻōpū, hoʻāla,
• nā ʻūlū ʻili, kūwili hoʻi, ka urticaria,
• ka māla ʻana
• hoʻonui nui momona
• ʻike maka
• nā kuhi maikaʻi ʻana - polyps and cysts,
• nā maʻi ʻeha hanu kiʻekiʻe.

I ka wā e mālama ʻia ai ka mālama ʻana, mālama ʻia ke kaupaona a me nā hōʻailona e hōʻike ana i ka mālama ʻana o ka wai. Hoʻohana ʻia nō hoʻi ka nānā ʻana o ka naʻau. ʻO ka hoʻohana ʻana i nā pahuhopu māmā o ka waiʻona ʻaʻole ia e hoʻopilikia i ka mana glycemic.

Dosage, ʻano o ka hoʻokele

Lawe ʻia nā Glitazones me ka ʻole e mālama i ka meaʻai. ʻAʻole hana ʻia ka hoʻoponopono ʻia ʻana no ka poʻe ʻelemakule me nā kekeʻe liʻiliʻi i loko o ke akea. Kahi ʻia ka ʻaoʻao o nā mea maʻi e kuhikuhi i kahi haʻahaʻa o kēlā lā i kēia lā i ka lāʻau. Hoʻoholo ʻia ka Doseage e ke kauka hoʻokahi.

Hoʻomaka ka hoʻomaka ʻana o nā lāʻau me kahi hōʻemi haʻahaʻa haʻahaʻa. Inā kūpono, hoʻonui ʻia i nā kukū ʻana ma luna o ka lāʻau lapaʻau. Ke hui pū ʻia me ka insulin, e loli ʻole kona ʻano o ke ʻano me ka ʻole o nā hōʻike o nā kūlana hypoglycemic.

Thiazolidinedione ʻAuhala Kauka

Loaʻa nā ʻelua inoa o glitazone ma ka mākeke lāʻau i kēia lā - rosiglitazone a me pioglitazone. ʻO ka mea mua i ka hui he troglitazone - ua hoʻopau koke ʻia ia ma muli o ka hoʻomohala ʻana o ka hōʻeha kino o ka pūpū.

Ke loaʻa nei nā lāʻau lapaʻau e pili ana i ka rosiglitazone:

• 4 mg avandia - Sepania,
• 4 mg Diagnitazone - Ukraine,
• Roglit ma ka 2 mg lāua ʻo 4 mg - ʻo Hūlani.

ʻO nā lāʻau lapaʻau Piogitazone e loaʻa:

• Glutazone 15 mg, 30 mg, 45 mg - Ukraine,
• Nilgar 15 mg, 30 mg - India,
• Dropia-Sanovel 15 mg, 30 mg - Turkey,
• Pioglar 15 mg, 30 mg - India,
• Pyosis 15 mg lāuaʻo 30 mg - India.

Hoʻopili me nā lāʻau lapaʻau ʻē aʻe

1. Rosiglitazone. ʻAʻole pili ka hoʻohana ʻana i ka waiʻona i ka mana glycemic ʻAʻohe ʻano nui o ka hui me nā tablet contaceptives, Nifedipine, Digoxin, Warfarin.
2. Pioglitazone. Ke hoʻohui a me ka rifampicin, hoʻemi ʻia ka hopena o ka pioglitazone. Malia paha kahi emi iki o ka hopena o ka contraception aʻo ka lawe ʻana i nā mea papa papa. Ke hoʻohana ʻana i ka ketoconazole, pono nui ka mālama glycemic.

ʻAʻole nā ​​Thiazolidinediones e hōʻemi wale i nā pae koko, akā hoʻopilikia maikaʻi hoʻi i ka ʻōnaehana cardiovascular. Ma waho aʻe o nā pono, loaʻa iā lākou kahi nui o nā hiʻohiʻona maikaʻi, ʻo ka mea maʻamau ka nui o ka hoʻomohala ʻana o ka hōʻeha ʻana o ka puʻuwai a me ka hoʻohaʻahaʻa ʻana i ka paʻa o ka iwi.

Hoʻohana pinepine lākou i ka lāʻau paʻakikī, ʻo ka hoʻohana ʻana i ka thiazolidinediones no ka pale ʻana i ka hoʻomohala ʻia o ka maʻi e pono ai ka noiʻi hou aku.